Form 4: Akari Therapeutics Director Acquires 1.4 Million Ordinary Shares
SEC Form 4 Filing
Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 1,400,000 ordinary shares at $0.0005 per share on December 23, 2024.
Summary
- On December 23, 2024, Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 1,400,000 ordinary shares.
- The purchase price was $0.0005 per ordinary share.
- Following the transaction, Patel indirectly owns 5,238,203,500 ordinary shares through PranaBio Investments LLC.
- Patel also directly owns 91,396,000 ordinary shares.
Sentiment
Score: 5
Explanation: This is a neutral report on insider trading activity. It doesn't inherently indicate positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction may have a minor impact on shareholders as it reflects an insider's investment in the company.
Key Dates
| Date | Description |
|---|---|
| 12/23/2024 | Date of transaction: Samir Rashmikant Patel acquired 1,400,000 Ordinary Shares at $0.0005 per share. |
| 12/26/2024 | Date of report: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.